The Next Wave of Influenza Drugs

Megan L. Shaw

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Options for influenza therapy are currently limited to one class of drug, the neuraminidase inhibitors. Amidst concerns about drug resistance, much effort has been placed on the discovery of new drugs with distinct targets and mechanisms of action, with great success. There are now several candidates in late stage development which include small molecules targeting the three subunits of the viral polymerase complex and monoclonal antibodies targeting the hemagglutinin, as well as host-directed therapies. The availability of drugs with diverse mechanisms now opens the door to exploring combination therapies for influenza, and the range of administration routes presents more opportunities for treating hospitalized patients.

Original languageEnglish
Pages (from-to)691-694
Number of pages4
JournalACS Infectious Diseases
Issue number10
StatePublished - 13 Oct 2017


Dive into the research topics of 'The Next Wave of Influenza Drugs'. Together they form a unique fingerprint.

Cite this